Cefepime Hydrochloride



Combined with:

Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 12.5%
Lung Infection 8.3%
Sepsis 8.3%
Tuberculosis 8.3%
Urinary Tract Infection 8.3%
Febrile Neutropenia 6.3%
Osteitis 6.3%
Pneumonia 6.3%
Arthritis Bacterial 4.2%
Diabetic Foot 4.2%
Grand Mal Convulsion 4.2%
Osteomyelitis 4.2%
Pleural Effusion 4.2%
Arthritis Infective 2.1%
Budd-chiari Syndrome 2.1%
Cellulitis 2.1%
Diabetic Ulcer 2.1%
Endocarditis 2.1%
Hypertension 2.1%
Liver Transplant 2.1%
Epilepsy 13.8%
Status Epilepticus 10.3%
Drug Administration Error 6.9%
Hepatic Enzyme Increased 6.9%
Jaundice 6.9%
Pyrexia 6.9%
Anaemia 3.4%
Cerebral Ischaemia 3.4%
Confusional State 3.4%
Death 3.4%
Drug Rash With Eosinophilia And Systemic Symptoms 3.4%
Haemodialysis 3.4%
Incorrect Dose Administered 3.4%
Neurotoxicity 3.4%
Osteomyelitis 3.4%
Rales 3.4%
Renal Failure 3.4%
Toxicity To Various Agents 3.4%
Tremor 3.4%
Urticaria 3.4%
Secondary
Product Used For Unknown Indication 30.7%
Drug Use For Unknown Indication 12.9%
Prophylaxis 7.1%
T-cell Type Acute Leukaemia 5.3%
Hypertension 4.4%
Nasopharyngitis 4.4%
Pneumonia 4.0%
Tuberculosis 3.6%
Infection Prophylaxis 3.1%
Antibiotic Therapy 2.7%
Antitussive Therapy 2.7%
B Precursor Type Acute Leukaemia 2.7%
Premedication 2.7%
Urinary Tract Infection 2.7%
Infection 2.2%
Acute Myeloid Leukemia 1.8%
Grand Mal Convulsion 1.8%
Myeloid Leukaemia 1.8%
Nausea 1.8%
Pain 1.8%
Fall 8.8%
Monocytopenia 8.8%
Pyrexia 8.8%
Drug Hypersensitivity 5.9%
Drug Rash With Eosinophilia And Systemic Symptoms 5.9%
Posterior Reversible Encephalopathy Syndrome 5.9%
Rash 5.9%
Toxic Encephalopathy 5.9%
Unresponsive To Stimuli 5.9%
Vomiting 5.9%
White Blood Cell Count Increased 5.9%
Agranulocytosis 2.9%
Atrial Fibrillation 2.9%
Cord Blood Transplant Therapy 2.9%
Drug Level Increased 2.9%
Immune Reconstitution Inflammatory Syndrome 2.9%
Low Birth Weight Baby 2.9%
Myoclonus 2.9%
No Adverse Reaction 2.9%
Pneumonia 2.9%
Concomitant
Product Used For Unknown Indication 20.2%
Prophylaxis 14.8%
Infection Prophylaxis 9.8%
Aplastic Anaemia 7.5%
Bone Marrow Conditioning Regimen 5.8%
Prophylaxis Against Graft Versus Host Disease 5.6%
Antifungal Prophylaxis 5.4%
Acute Myeloid Leukaemia 5.2%
Premedication 3.8%
Antiviral Prophylaxis 3.2%
Prophylaxis Against Gastrointestinal Ulcer 2.8%
Antibiotic Prophylaxis 2.5%
Graft Versus Host Disease 2.2%
Febrile Neutropenia 2.1%
Acute Graft Versus Host Disease 2.0%
Drug Use For Unknown Indication 1.6%
Infection 1.5%
Hypertension 1.5%
Constipation 1.2%
Insomnia 1.2%
Pyrexia 13.2%
White Blood Cell Count Decreased 8.8%
Sepsis 8.2%
Staphylococcal Sepsis 8.2%
Febrile Neutropenia 7.5%
Staphylococcal Infection 6.3%
Acute Graft Versus Host Disease In Skin 5.0%
Interstitial Lung Disease 4.4%
Pseudomonal Sepsis 4.4%
Stomatitis 4.4%
Cystitis Haemorrhagic 3.8%
Urinary Tract Infection 3.8%
Infection 3.1%
Therapeutic Response Decreased 3.1%
Viral Haemorrhagic Cystitis 3.1%
Acute Myeloid Leukaemia Recurrent 2.5%
Cerebral Haemorrhage 2.5%
Herpes Zoster 2.5%
Platelet Count Decreased 2.5%
Pulmonary Oedema 2.5%
Interacting
Atrial Flutter 25.0%
Pneumonia 25.0%
Pulmonary Embolism 25.0%
Pain 12.5%
Pain In Extremity 12.5%
Retroperitoneal Haematoma 100.0%